Q2 sales grew 4% sequentially but fell 20% year-over-year due to New York Medicaid changes, prompting a successful pivot to the commercial segment, which saw strong prescription and prescriber growth. H1 revenue rose 41% year-over-year, and profitability was achieved.Based on Shield Therapeutics Pl…
Q2 sales grew 4% sequentially but fell 20% year-over-year due to New York Medicaid changes, prompting a successful pivot to the commercial segment, which saw strong prescription and prescriber growth. H1 revenue rose 41% year-over-year, and profitability was achieved.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
